After its $7.6B buyout fell through, Sobi scores NICE backing for rare disease drug Aspaveli
After rare disease drugmaker Sobi reportedly had a buyout scuppered by pharma giant AstraZeneca, the company has picked up a win that stands to bolster its Aspaveli l...
Continue Reading →
